Stay updated with breaking news from Felix feng. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cancer Liquid Biopsy Developer Bluestar Raises $70M, Adds Venter to Scientific Advisory Board May 21, 2021 J. Craig Venter, Ph.D. Bluestar Genomics, the developer of an epigenomic platform focused on early cancer detection, has raised $70 million in an oversubscribed Series C equity financing and named genomics pioneer J. Craig Venter, Ph.D., among two new members of its expanded scientific advisory board. “Collectively, these milestones will extend our ability to deliver on our promise to improve on existing cancer screening and provide a new solution where none exists,” Samuel Levy, Ph.D., Bluestar’s CEO and Chief Scientific Officer, said in a statement. ....
Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, today announced the . ....
Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Decipher Test Clinically Validated as a Predictor of Overall Survival in Men with Prostate Cancer Decipher test validated in study of the practice-changing Phase 3 RTOG 96-01 clinical trial News provided by Share this article Share this article SAN DIEGO, Feb. 11, 2021 /PRNewswire/ Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers, today announced publication of the results, in JAMA Oncology, from an analysis of the NRG Oncology Phase 3 randomized controlled trial RTOG 96-01. In this study, the Decipher Prostate RP, a radical prostatectomy post-surgery test, was clinically validated to predict overall survival and is believed to be the first known genomic test in localized prostate cancer to accomplish this milestone. The study, which followed patients for a median of 12 years, validated the Decipher RP test as an independent pred ....